Home / Health / Glenmark's Innovative Nasal Spray Approved in China for Allergic Rhinitis
Glenmark's Innovative Nasal Spray Approved in China for Allergic Rhinitis
10 Nov
Summary
- Glenmark's RYALTRIS nasal spray approved in China for allergic rhinitis
- Approval covers adults and children, with no supplementation requests
- RYALTRIS combines antihistamine and corticosteroid to treat rhinitis symptoms
On November 10, 2025, Glenmark Pharmaceuticals announced that its wholly-owned subsidiary, Glenmark Specialty S.A., has received approval from China's National Medical Products Administration (NMPA) for its RYALTRIS Compound Nasal Spray. The approval covers the treatment of moderate to severe seasonal allergic rhinitis in adults and pediatric patients aged six years and older, as well as moderate to severe perennial allergic rhinitis in adults and pediatric patients aged twelve years and older.
The NMPA approval, granted without any supplementation requests, marks an important milestone in Glenmark's respiratory pipeline. The company stated that the approval reflects its continued progress in advancing innovative and differentiated therapies for patients with chronic conditions.
RYALTRIS is a first-of-its-kind fixed-dose combination nasal spray that brings together an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) to treat the symptoms of allergic rhinitis. The approval follows the successful completion of a Phase III clinical trial in China, which enrolled 535 patients across multiple trial centers. The results demonstrated that RYALTRIS outperformed monotherapy comparators in efficacy scores, while also meeting endpoints for safety, tolerability, and pharmacokinetics.
